 5. Relapsed or refractory disease, defined as either: 1 recurrence of disease after a CR, or 2 PR, SD, or progressive disease PD at completion of the treatment regimen preceding entry to the study residual disease: Subjects must have previously received an appropriate first-line treatment regimen. Subjects who have not received HDTASCT must be ineligible for HDTASCT 